EGFR and cancer: We also demonstrated the inability of the bispecific Nanofitin to use the pre-anchoring activity in low EGFR expressing cells despite the high levels of PDL1, which support its selectivity for cancer cells with moderate to high levels of EGFR et PDL1 and a lack of engagement of healthy cells.